Tony Vangeneugden

TL;DR: In lopinavir-naive, treatment-experienced patients, darunavir-ritonavir was non-inferior to lop Scandinavian-rit onavir treatment in terms of the virological endpoint, and should therefore be considered as a treatment option for this population.

TL;DR: In this population of treatment-experienced patients, darunavir/r demonstrated significantly greater efficacy than investigator-selected control PIs of trials POWER 1 and 2, regardless of baseline viral genotype or phenotype, while exhibiting a high genetic barrier to the development of resistance.

TL;DR: Darunavir/rtv should be administered with food, but exposure to darunavIR is not affected by the type of meal, as no significant differences in dar unavir plasma concentrations were observed between different fed states.

TL;DR: Treatment with DRV/r 600/100 mg twice daily was well tolerated and led to sustained virological and immunological responses in treatment-experienced HIV-1-infected patients over 96 weeks.